MDM2 and cancer: MDM2, an E3 ubiquitin‐protein ligase and also known as oncoprotein, is critically involved in the advancement of cancer and the development of therapeutic resistance of chemotherapy (such as cisplatin, doxorubicin, gemcitabine and 5‐FU), radiotherapy, targeted agents (such as tyrosine kinase inhibitors).41